Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression.

Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression.

<p>The cell populations are healthy marrow cells (<i>A</i>), CD38+ cancer and CD38− cancer , and all arrows represent movement of cells between populations or states. Three drug actions are included (green arrows): cell mortality and loss of CD38 expression in the CD38+ cancer cell...

保存先:

書誌詳細
第一著者:	James G. Lefevre (11303976) (author)
その他の著者:	Brodie A. J. Lawson (8771843) (author), Pamela M. Burrage (16938568) (author), Diane M. Donovan (22033185) (author), Kevin Burrage (21168) (author)
出版事項:	2025
主題:	Biophysics Biochemistry Medicine Genetics Pharmacology Biotechnology Cancer Hematology Infectious Diseases Biological Sciences not elsewhere classified target drug effects plasma cell cancer monoclonal antibody daratumumab target drug effect healthy cells due cd38 expression switches optimal treatment regime drug resistance mechanisms healthy cells drug action cd38 expression cancer cells optimal treatment added mechanisms optimal control myeloma cells leading treatment express cd38 daratumumab treatment cd38 receptor proposed mechanism ode model lower fitness indirect effect identified within highly overexpressed general increase direct effect bone marrow
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Model parameters with descriptions and default values. The right-hand side column gives the parameter values for a simplified model (Null-N).
著者:: James G. Lefevre (11303976)
出版事項: (2025)

Optimal control solutions for the linear cost function with zero or default off-target drug effect (), no immune response (), reduced expression switching (, default ), and induced loss of expression set to either zero or the default value ().
著者:: James G. Lefevre (11303976)
出版事項: (2025)

Selected optimal control solutions for the linear cost function where either expression switching (top row, ) or drug induced loss of expression (bottom row, ) is removed from the model.
著者:: James G. Lefevre (11303976)
出版事項: (2025)

Optimal control solutions for the linear cost function with increased off-target drug effect (; default 0.1), reduced expression switching (, default ), reduced or default immune strength (, default 0.15), and default or increased drug induced loss of expression (, default 0.2).
著者:: James G. Lefevre (11303976)
出版事項: (2025)

Optimal control solutions for different off-target drug effect magnitudes (); default value .
著者:: James G. Lefevre (11303976)
出版事項: (2025)

Optimal control solutions for a range of values of <i>α</i>, which controls the strength of the immune response; default value is .
著者:: James G. Lefevre (11303976)
出版事項: (2025)

Optimal controls for the full model developed in this paper (Full model) and a simplified version with drug resistance mechanisms and the off-target effect removed (Null-N).
著者:: James G. Lefevre (11303976)
出版事項: (2025)

Model validation and comparison with Null-N model.
著者:: James G. Lefevre (11303976)
出版事項: (2025)

Pharmacokinetics and Exposure-response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
著者:: Xu Steven Xu (5817798)
出版事項: (2018)

DataSheet_6_Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.docx
著者:: Lu Ye (1978777)
出版事項: (2023)

DataSheet_4_Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.docx
著者:: Lu Ye (1978777)
出版事項: (2023)

DataSheet_5_Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.docx
著者:: Lu Ye (1978777)
出版事項: (2023)

DataSheet_1_Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.docx
著者:: Lu Ye (1978777)
出版事項: (2023)

DataSheet_2_Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.docx
著者:: Lu Ye (1978777)
出版事項: (2023)

DataSheet_3_Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.docx
著者:: Lu Ye (1978777)
出版事項: (2023)

Daratumumab: A Review in Relapsed or Refractory Multiple Myeloma
著者:: Hannah A. Blair (5008301)
出版事項: (2018)

Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
著者:: Yvette Lamb (6930427)
出版事項: (2020)

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma infographic
著者:: Barry Paul (14874363)
出版事項: (2023)

Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia
著者:: Adis journals on behalf of (9646730)
出版事項: (2021)

DataSheet_1_Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia.pdf
著者:: Maria A. Pereda (14188328)
出版事項: (2022)

Early daratumumab-based therapy demonstrates significant effectiveness in patients with relapsed and refractory multiple myeloma: a real-world retrospective investigation
著者:: Yi Chen (38576)
出版事項: (2025)

Image_2_Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.tif
著者:: Niklas Baumann (13257681)
出版事項: (2022)

Image_1_Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.tif
著者:: Niklas Baumann (13257681)
出版事項: (2022)

Table_1_Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE.docx
著者:: Morgane Humbel (10338491)
出版事項: (2021)

Timeline of dara treatment and occurrence of infectious complications of all patients.
著者:: Hareth Nahi (594713)
出版事項: (2019)

Waterfall plot of changes of M-component in response to dara treatment.
著者:: Hareth Nahi (594713)
出版事項: (2019)

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated With Daratumumab Monotherapy
著者:: Adis journals on behalf of (9622094)
出版事項: (2021)

Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
著者:: Adis journals on behalf of (9646728)
出版事項: (2021)

Clinical and immunological parameters from a patient with VZV reactivation during dara treatment.
著者:: Hareth Nahi (594713)
出版事項: (2019)

Clinical and immunological parameters from a patient with HSV infection during dara treatment.
著者:: Hareth Nahi (594713)
出版事項: (2019)

Clinical and immunological parameters from a patient who received Allo-SCT and dara treatment.
著者:: Hareth Nahi (594713)
出版事項: (2019)

Clinical and immunological parameters from an 82y male patient with CMV reactivation during dara treatment.
著者:: Hareth Nahi (594713)
出版事項: (2019)

DataSheet_1_Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.pdf
著者:: Yang Gao (18005)
出版事項: (2021)

Clinical and immunological parameters from a 65y male patient with CMV reactivation during dara treatment.
著者:: Hareth Nahi (594713)
出版事項: (2019)

Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan
著者:: Kazuhito Suzuki (22688384)
出版事項: (2025)

Table 2_The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis.docx
著者:: Huixing Zhou (9561557)
出版事項: (2025)

Table 1_The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis.docx
著者:: Huixing Zhou (9561557)
出版事項: (2025)

Data Sheet 1_The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis.pdf
著者:: Huixing Zhou (9561557)
出版事項: (2025)

Effect of ATRA on p38-MSK cascade activation in myeloma cells.
著者:: Zhiqiang Liu (182265)
出版事項: (2014)

Antigen specificity index (ASI) of anti-CD38-IFNα and attenuated variants.
著者:: Sarah L. Pogue (3111267)
出版事項: (2016)